IR Exposure

Evidence Required to Establish Exposure from T&N Entity Asbestos Products

To meet the exposure requirements, the claimant must show credible evidence, for any or all Disease Levels, Federal-Mogul Company Exposure for the relevant T&N Entity and Significant Occupational Exposure as defined in section 5.7(b) of the TDP. In the case of Disease Levels II – VIII, payments may be either greater or less than the ER payment that a claimant might have received.

Federal-Mogul Exposure must include the following:

• Claimant must demonstrate credible exposure, which occurred prior to December 31, 1982, to asbestos or asbestos containing products supplied, manufactured, installed, maintained, or repaired by the relevant T&N Entity and/or any entity, including any contracting unit, for which the particular Federal-Mogul Entity has legal responsibility.
• Worked at an approved T&N Entity site prior to December 31, 1982, in proximity of relevant T&N Entity product, or in the proximity of the performance of services by a T&N Entity, including a T&N Entity contracting unit.
• For sites that are not on the relevant job site list, the Trust will consider the following:
  • An affidavit, sales, construction, employment, or other similar records that establishes that their product was present at the time of the alleged exposure

Significant Occupational Exposure means employment for a cumulative period of at least five years with a minimum of two years prior to December 31, 1982, in an industry and an occupation in which the claimant:

1. Handled raw asbestos fibers on a regular basis;
2. Fabricated asbestos-containing products so that the claimant in the fabrication process was exposed on a regular basis to raw asbestos fibers;
3. altered, repaired or otherwise worked with an asbestos-containing product such that the claimant was exposed on regular basis to asbestos fibers; or
4. was employed in an industry and occupation such that the claimant worked on a regular basis in close proximity to workers engaged in the activities described in (1), (2) and/or (3).